ArcaScience Daily Commercial Intelligence Report

Description

Generate a comprehensive daily commercial intelligence report identifying 8 actionable European regulatory opportunities for ArcaScience's BRA platform. Output as a professionally formatted .docx file.

Trigger

Use this skill when the user asks to:

• Generate a daily prospection/intelligence report
• Find commercial targets or opportunities in pharma
• Research European regulatory developments for ArcaScience
• Create a "pulse" or "intel" report
• Run the daily prospection task

Also triggered automatically by the daily-prospection-intel cron job.

Instructions

Phase 1: Research (Web Search Required)

Search for the latest European regulatory developments from the past 24-48 hours. Run ALL of these searches:

1. EMA/CHMP opinions: Search site:ema.europa.eu CHMP opinion 2026 and EMA CHMP positive negative opinion this week
2. Marketing authorizations: Search EMA new marketing authorization application validated 2026
3. PRAC signals: Search EMA PRAC safety signal referral 2026
4. Priority pathologies: Search each of these individually:
   • TNBC triple negative breast cancer EMA regulatory 2026
   • hidradenitis suppurativa EMA CHMP 2026
   • rheumatoid arthritis EMA new treatment 2026
5. Adjacent pathologies: Search EMA CHMP negative opinion re-examination 2026 and biosimilar CHMP positive opinion 2026
6. Clinical readouts: Search phase 3 results Europe oncology immunology 2026

For each finding, verify the regulatory trigger is SPECIFIC and RECENT (within the last week ideally).

Phase 2: Target Selection & Prioritization

Select exactly 8 targets following this STRICT priority framework:

PRIORITY 1 (minimum 3 targets): Core pathologies — TNBC, Hidradenitis Suppurativa, Rheumatoid Arthritis. If fewer than 3 opportunities exist in these exact pathologies, expand to biologically adjacent areas:

• TNBC adjacent: other breast cancers, ADC therapies, TROP2/HER2 targets
• HS adjacent: atopic dermatitis, psoriasis, JAK inhibitor applications
• RA adjacent: lupus, ankylosing spondylitis, psoriatic arthritis, other anti-TNF/JAK/IL-6 targets

PRIORITY 2 (minimum 2 targets): Biologically adjacent pathologies — rare neuro, neuromuscular, pediatric rare diseases, immune-mediated inflammatory diseases.

PRIORITY 3 (minimum 3 targets): Lowest-hanging fruits most compatible with ArcaScience technology — regardless of pathology:

• Biosimilar evidence strategies (multi-indication, interchangeability)
• CHMP negative opinions needing re-examination (HIGHEST VALUE — companies are desperate)
• Complex multi-indication filings
• Pediatric investigation plan challenges
• Lifecycle management / Type II variations with evidence gaps

Phase 3: Intelligence Compilation

For EACH of the 8 targets, compile:

1. Company: Full legal entity name (EU subsidiary if applicable)
2. Molecule: INN (brand name) — include mechanism of action
3. Indication: Specific therapeutic indication under regulatory review
4. Pathology: Disease area
5. Regulatory Status: Current EMA/CHMP/PRAC status with exact dates
6. Regulatory Trigger (2-3 paragraphs): What happened, why it matters NOW, what the company needs. Be SPECIFIC — reference committee meeting dates, vote outcomes, methodology concerns raised, competitive dynamics.
7. ArcaScience Narrative & Positioning (3-4 bullet points): How ArcaScience SPECIFICALLY addresses this company's challenge. Reference concrete ArcaScience capabilities:
   • Evidence mapping & cross-indication harmonization
   • Regulatory gap analysis (pre-empting CHMP questions)
   • Endpoint & statistical narrative alignment
   • Bridging strategies (pediatric, geographic, cross-study)
   • Dynamic benefit-risk modeling (continuous vs. periodic)
   • Post-marketing RWE study design
   • Multi-indication HTA evidence strategy
   • Re-examination evidence reconstruction (for negative opinions)
8. Key Contacts / Outreach Target: Role titles and locations (EU regulatory affairs lead, CMO, VP PV, etc.). Reference the company dossiers in arcascience_dossiers/companies/ if available.
9. Outreach Email Template: A COMPLETE, ready-to-send email (see Email Template Rules below).

Phase 4: Document Generation

Generate the report as a .docx file using docx-js. The file MUST follow this exact structure:

Page 1: Cover

• "ARCASCIENCE" (bold, large)
• "DAILY COMMERCIAL INTELLIGENCE REPORT"
• "European Regulatory Pulse — Targeted Opportunities"
• Today's date
• "8 Commercial Targets | 3 Priority Tiers | Europe Focus"

Priority Legend

• ● PRIORITY 1: TNBC | Hidradenitis Suppurativa | Rheumatoid Arthritis
• ● PRIORITY 2: Biologically adjacent pathologies
• ● PRIORITY 3: Lowest-hanging fruits — biosimilar evidence & lifecycle strategy

Executive Summary

4-6 bullet points highlighting the KEY signals of the day. Emphasize:

• Urgency (negative opinions, re-examinations, competitive races)
• ArcaScience-specific relevance
• Market size / strategic importance

Targets #1 through #8

Each target gets its own section with all 9 elements from Phase 3.

File naming

ArcaScience_Daily_Intel_YYYYMMDD.docx

Save to the workspace folder.

Email Template Rules

Every outreach email MUST follow this structure:

Subject: [Specific regulatory trigger] — [ArcaScience capability match]

Dear [Role Title],

[Opening paragraph: Reference the SPECIFIC regulatory event. Show you know what happened and why it matters to them. 2-3 sentences max.]

[Value paragraph: Position ArcaScience as the solution to their specific challenge. Reference their pipeline, their regulatory history, their competitive context. 3-4 sentences.]

Specifically, we can support:

• [Capability 1 — tied to their specific situation]
• [Capability 2 — tied to their specific situation]
• [Capability 3 — tied to their specific situation]

[Closing: Suggest a 30-minute call. Be specific about timing if possible.]

Best regards,
[Your name]
ArcaScience

Rules:

• NEVER use generic language like "your organization" or "companies like yours"
• ALWAYS reference the specific molecule, indication, and regulatory event
• ALWAYS include at least 3 specific capability bullets
• Subject line must be under 80 characters and reference the trigger
• Language: English (report and emails are always in English)

References

Embedded References (in this skill's references/ folder)

• references/arcascience-context.md — Full company context & positioning
• references/sales-package-platform.md — BRA platform deck, one-pagers, evidence infrastructure
• references/sales-package-proposals.md — Client proposals (Dilon, Sanofi, Asphalion) & BRA analysis
• references/sales-package-personae.md — Buyer personae analysis (14 personas with scoring)
• references/sales-package-operations.md — Sales org process, contracts templates

External Dossiers (in the GitHub repo — read on demand)

• Company dossiers: C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\companies\ (100 files)
• Stakeholder profiles: C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\stakeholders\
• Master targeting table: C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\master_targeting_table.csv
• Company list: C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\COMPANY_LIST.md

Quality Checklist (Self-Verify Before Delivering)

• Exactly 8 targets (not 7, not 9)
• At least 3 Priority 1, 2 Priority 2, 3 Priority 3
• Every regulatory trigger references a SPECIFIC event with a date
• Every ArcaScience narrative has at least 3 SPECIFIC capability bullets
• Every email template is customized (no copy-paste with name changes)
• No targets older than 1 week unless re-examination is ongoing
• .docx file is properly formatted and saved to workspace
• File named ArcaScience_Daily_Intel_YYYYMMDD.docx